Personal Finance

Here's Why Alnylam Pharmaceuticals Plunged 59.8% in 2016

ALNY Chart
ALNY Chart

ALNY data by YCharts .

So what

While Alnylam's share price was weak through the first nine months of the year, investors can mostly chalk that up to the general sell-off in biotech. However, the company's stock was decimated in October after the company reported a major clinical setback.

On Oct. 5, management stated that the company was discontinuing development of revusiran, a compound that was aimed at treating hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM), a rare condition that can lead to heart failure. The decision was made in response to a recommendation made by an independent monitoring committee that was watching the drug's late-stage trials.

The committee concluded that the potential benefits of using revusiran were not high enough to outweigh its risks after several patients involved in the trials had died or suffered nerve damage. Management agreed with that bleak assessment and abandoned all future development.

Since revusiran was believed to hold blockbuster potential and was one of the company's most advanced compounds, the update didn't sit well with investors. Shares fell by more than 48% on the day of the announcement and have yet to recover.

Now what

Management was quick to point out that its decision to stop development on revusiran would not impact any of their other RNAi drugs in development. Importantly, this includes patisiran, which is another compound that's being studied as a treatment for ATTR amyloidosis. Top-line data for patisiran's late-stage clinical trials is still expected to be available in the second half of 2017 , which gives investors hope that Alnylam can still transform itself into a commercial enterprise as early as 2018.

That being said, there's no doubt that revusiran's failure was a huge blow to shareholders. Not only did it remove a potential blockbuster drug from hitting the market, but it also raised serious safety questions about the rest of the company's pipeline that utilizes the company's gene silencing RNAi technology. If future studies also show that this drug-making technique is too unsafe for real-world uses, there could still be a lot more pain ahead for shareholders.

Given that there are so many unknowns, I think the smart move for potential investors to make is to take a wait-and-see approach to this risky biotech.

10 stocks we like better than Alnylam Pharmaceuticals

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Alnylam Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of Nov. 7, 2016

Brian Feroldi has no position in any stocks mentioned.Like this article? Follow him on Twitter where he goes by the handle @BrianFeroldi , or connect with him onLinkedInto see more articles like this.

The Motley Fool owns shares of and recommends Alnylam Pharmaceuticals. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More